文献速递泌尿男性生殖肿瘤

血浆雄激素受体状态与适配及标准多西他赛方案治疗去势抵抗性前列腺癌的应答:一项多中心生物标志物研究

Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study.
PubMed 文献 · Eur J Cancer · 2021-05-30

该多中心回顾性研究纳入325例接受标准或适配多西他赛方案的转移性去势抵抗性前列腺癌(mCRPC)患者,采用微滴数字PCR检测基线血浆AR拷贝数状态。在训练队列中,AR增益患者接受适配剂量多西他赛的无进展生存期、总生存期和PSA应答均显著差于AR正常患者,验证队列证实了这些发现;但标准剂量组未见差异。AR拷贝数状态与多西他赛减量的交互作用为PFS的独立影响因素。

要点

  • 血浆AR增益与mCRPC患者接受适配剂量多西他赛的不良预后显著相关。
  • 标准剂量多西他赛组中,血浆AR状态与预后差异无显著关联。
  • AR拷贝数状态与剂量减量的交互作用是PFS的独立影响因素。

核心结论

  • 尽管为回顾性非随机设计,该假设生成性研究提示血浆AR可能作为mCRPC患者优化多西他赛时机和剂量的潜在生物标志物,需前瞻性试验验证。

研究设计与样本

  • 多机构研究,纳入325例接受标准或适配多西他赛方案的mCRPC患者,基线血浆AR拷贝数状态通过微滴数字PCR评估。
  • 分析时患者被随机分配至训练队列(n=217)或验证队列(n=108)。

主要发现

  • 训练队列中,AR增益患者接受适配多西他赛方案的中位无进展生存期为3.8个月 vs 6.3个月(HR 2.58,95%CI 1.34-4.95,p<0.0001),中位总生存期为10.8个月 vs 20.6个月(HR 1.98,95%CI 1.09-3.62,p=0.0064),PSA应答(PSA > -50%)的比值比为4.88(95%CI 1.55-14.32,p=0.013),均显著差于血浆AR正常患者。
  • 上述发现在验证队列中均得到证实。
  • 在接受标准多西他赛方案的患者中,未观察到这些差异。
  • AR拷贝数状态与多西他赛剂量减量的交互作用在训练队列和验证队列中均被视为PFS的独立影响因素(HR 2.84,95%CI 1.41-5.73,p=0.003;HR 4.79,95%CI 1.79-12.82,p=0.002)。

临床怎么用

  • 血浆AR状态可能有助于识别从适配剂量多西他赛方案中获益较差的患者,提示需考虑标准剂量或替代治疗策略。

局限性

  • 研究为回顾性非随机设计,结果属假设生成性,需前瞻性试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plasma AR status has been identified as a potential biomarker of response in metastatic castration-resistant prostate cancer (mCRPC) patients receiving docetaxel or AR-targeted therapies. However, the relevance of plasma AR in the overall management of CRPC patients receiving different docetaxel doses is unknown. PATIENTS AND METHODS: This was a multi-institution study of associations between baseline plasma AR copy number status, assessed by droplet digital PCR, and outcome in 325 mCRPC patients receiving docetaxel at standard or adapted regimen at the discretion of the treating physician. Upon analysis, patients were assigned randomly to either a training (n = 217) or validation (n = 108) cohort. RESULTS: In the training cohort, AR-gained patients treated with adapted docetaxel regimen had a significantly worse median progression-free survival (PFS) (3.8 vs 6.3 months, hazard ratio [HR] 2.58, 95% confidence interval [CI] 1.34-4.95, p < 0.0001), median overall survival (10.8 vs 20.6 months, HR 1.98, 95% CI 1.09-3.62, p = 0.0064) and PSA response (PSA > -50%: odds ratio 4.88 95%CI 1.55-14.32, p = 0.013) as compared to plasma AR normal patients. These findings were all confirmed in the validation cohort. However, in patients treated with standard docetaxel regimen, these differences were not seen. The interaction between AR CN status and dose reduction of docetaxel was considered as independent factor for PFS in both the training and validation cohort (HR 2.84, 95% CI 1.41-5.73, p = 0.003, and HR 4.79, 95% CI 1.79-12.82, p = 0.002). CONCLUSION: Despite the retrospective non-randomised design of this study, our hypothesis-generating findings could suggest plasma AR as a potential biomarker for optimal docetaxel timing and dose in mCRPC patients. Prospective trials are warranted.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Conteduca V, Wetterskog D, Castro E, et al. Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. Eur J Cancer. 2021. PMID: 34077818. doi:10.1016/j.ejca.2021.04.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。